Co-Founder, President & Chief Executive Officer
Niven R. Narain is Co-Founder, President, & CEO of BERG. His foremost passion is to improve healthcare systems and patient care through the fusion of AI and patient biology to develop the next generation of therapeutics. As CEO, Niven drives the vision of BERG's translational engine from discovery to clinical development and ensures that BERG is collaborating with like-minded institutions to advance product development. He discovered Interrogative Biology®, BERG’s flagship platform that has created a robust pipeline of products in cancer, diabetes, and CNS diseases. BPM 31510 is BERG’s lead asset in solid tumors which is currently in Phase II trials. He is inventor on over 600 issued and pending patents over a diverse range of assets in drugs and diagnostics.
Senior Vice President & Chief Analytics Officer
Slava Akmaev, Ph.D. is the Senior Vice President and Chief Analytics Officer, leading the Analytics division. Dr. Akmaev is an avid advocate for the application of Artificial Intelligence tools in digital healthcare. He is a frequent speaker at Precision Medicine and Big Data meetings. Prior to his role at BERG Dr. Akmaev was the Scientific Associate Director at Genzyme Genetics where he launched multiple commercial diagnostic products. While at Genzyme R&D he led the development of novel statistical approaches for high-throughput "omics" data and performed analytical work in genomics and genetics. Dr. Akmaev published numerous manuscripts in genomics and was one of the early developers of analytical methodology around high-throughput molecular data. He co-authored the publication of the Long SAGE™ technology, "Using the transcriptome to annotate the genome" in Nature Biotechnology. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder. He is a recipient of the prestigious fellowship from The Program in Mathematics and Molecular Biology.
Vice President of Administration & Chief of Staff
Poornima Tekumalla, Ph.D, is the Vice President of Administration and Chief of Staff at BERG. In her role she supports the President and CEO to address needs of all stakeholders, Board of Directors and Senior Management. She serves as a liaison between the Office of the CEO and staff. She also manages external collaborations, due diligence logistics and budgeting.
Senior Vice President & Chief Scientific Officer
Ranga Sarangarajan, Ph.D., is the Senior Vice President and Chief Scientific Officer at BERG who oversees all research and development activities. Dr. Sarangarajan is the co-inventor and co-architect of the BERG Interrogative Biology® technology, and leads the implementation of scientific strategies and overall operations of the multi-functional integrated scientific program intersecting science and technology. He is responsible for developing strategies for rapid validation of preclinical and translation into clinical development and beyond of drug targets, therapeutics and biomarkers in the areas of cancer, cardiovascular and metabolic diseases, neurological diseases and other area(s) of BERG focus.
Sarah Toomey, Esq., joined BERG in 2017, bringing more than 13 years of legal experience as a strategic attorney with a background in biotechnology, corporate law and intellectual property. At BERG, Ms. Toomey is responsible for managing the Legal Department, including identifying and resolving business and legal issues; providing counsel on general corporate matters, including corporate strategies and initiatives; managing the company’s transactional agreements; advising on corporate governance; and overseeing BERG’s intellectual property portfolio.
Vice President of Human Resources
Kelly Capra, M.S., joined BERG in 2017. At BERG Ms. Capra is responsible for the Human Resource function of the company with a concentrated effort on building talent and culture and driving employee engagement. Ms. Capra is a seasoned HR Leader with 25 years of broad experience in a number of well-known companies such as Repligen, Dassault Systèmes, Stryker Biotech, Olympus Biotech and Boston Scientific.
Vice President of Finance & Controller
Kevin Coveney is the Vice President of Finance and Controller at BERG. Mr. Coveney drives the company’s financial operations and oversees its corporate Financial, Planning & Analysis and Accounting & Finance departments. Mr. Coveney has more than 25 years of financial management experience including public accounting, SEC reporting experience as well as financial management and reporting in the biotech and technology industries.
Chief Precision Medicine Officer
Michael Kiebish, PhD is the Chief Precision Medicine Officer. Michael joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure target populations’ are stratified based on biological and physiological status. Through the implementation of artificial intelligence platforms, BIG Data integration, population health strategies, and integrative phenomic technologies, the systems medicine division overseen by Dr. Kiebish synergizes BERG’s efforts in improving patient care, stratifying populations, and guiding molecular adaptive clinical trials.
Chief Technology Officer
In his role as Chief Technology Officer, Dr. Vivek Vishnudas oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology®. He leads an interdisciplinary team of drug-discovery scientists, biochemists and DMPK scientists to illuminate target biology & pharmacology, while working closely with regulatory, analytics and biomarker teams. Dr. Vishnudas manages the external R&D collaboration with industrial and academic partners, and aims to scale up Berg’s R&D therapeutics portfolio. He is a co-inventor of the Interrogative Biology® technology, and continues to spearhead development activities of “data-driven” technologies that enable drug discovery programs. His breadth of operations covers scientific leadership, strategic R&D initiatives and commercial and intellectual property strategies.